Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph M Meyer

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2002
Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimenRichard J Klasa, Ralph M Meyer, Chaim Shustik, et al.
Plos One|April 5, 2013
Treatment success in cancer: industry compared to publicly sponsored randomized controlled trialsBenjamin Djulbegovic, Ambuj Kumar, Branko Miladinovic, et al.
Current Oncology (Toronto, Ont.)|April 3, 2021
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical TrialAnca Prica, Annette E Hay, Michael Crump, et al.
Current Oncology (Toronto, Ont.)|April 3, 2021
A Canadian Prospective Study of Linkage of Randomized Clinical Trial to Cancer and Mortality Registry DataAnnette E Hay, Nicole Mittmann, Michael Crump, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplantA Keith Stewart, Christine I Chen, Kang Howson-Jan, et al.
Transfusion|June 27, 2002
A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced plateletsNancy M Heddle, Morris A Blajchman, Ralph M Meyer, et al.
Leukemia & Lymphoma|June 9, 2016
Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup/>Tara Baetz, Bingshu E Chen, Stephen Couban, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 19, 2015
Effect of re-irradiation for painful bone metastases on urinary markers of osteoclast activity (NCIC CTG SC.20U)Edward Chow, Carlo DeAngelis, Bingshu E Chen, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2015
Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I StudyRena Buckstein, Graeme Fraser, Matthew Cheung, et al.
British Journal of Haematology|October 11, 2014
Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10Michael J Kovacs, Gwynivere A Davies, Judy-Anne W Chapman, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2002
Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimenRichard J Klasa, Ralph M Meyer, Chaim Shustik, et al.
Plos One|April 5, 2013
Treatment success in cancer: industry compared to publicly sponsored randomized controlled trialsBenjamin Djulbegovic, Ambuj Kumar, Branko Miladinovic, et al.
Current Oncology (Toronto, Ont.)|April 3, 2021
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical TrialAnca Prica, Annette E Hay, Michael Crump, et al.
Current Oncology (Toronto, Ont.)|April 3, 2021
A Canadian Prospective Study of Linkage of Randomized Clinical Trial to Cancer and Mortality Registry DataAnnette E Hay, Nicole Mittmann, Michael Crump, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplantA Keith Stewart, Christine I Chen, Kang Howson-Jan, et al.
Transfusion|June 27, 2002
A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced plateletsNancy M Heddle, Morris A Blajchman, Ralph M Meyer, et al.
Leukemia & Lymphoma|June 9, 2016
Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup/>Tara Baetz, Bingshu E Chen, Stephen Couban, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 19, 2015
Effect of re-irradiation for painful bone metastases on urinary markers of osteoclast activity (NCIC CTG SC.20U)Edward Chow, Carlo DeAngelis, Bingshu E Chen, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2015
Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I StudyRena Buckstein, Graeme Fraser, Matthew Cheung, et al.
British Journal of Haematology|October 11, 2014
Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10Michael J Kovacs, Gwynivere A Davies, Judy-Anne W Chapman, et al.
Pageof 8